Article
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Cancer medicine - 1 Feb 2016
Malagola Michele, Skert Cristina, Borlenghi Erika, Chiarini Marco, Cattaneo Chiara, Morello Enrico, Cancelli Valeria, Cattina Federica, Cerqui Elisa, Pagani Chiara, Passi Angela, Ribolla Rossella, Bernardi Simona, Giustini Viviana, Lamorgese Cinzia, Ruggeri Giuseppina, Imberti Luisa, Caimi Luigi, Russo Domenico, Rossi Giuseppe
Abstract excerpt
Risk stratification in acute myeloid leukemia (AML) patients using prognostic parameters at diagnosis is effective, but may be significantly improved by the use of on treatment parameters which better define the actual sensitivity to therapy in the single patient. Minimal residual disease (MRD) monitoring has been demonstrated crucial for the identification of AML patients at high risk of relapse, but the best...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.